These five Dow Jones industrial companies have paid dividends for at least 100 years, perfect ideas for long-term growth and ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

In honor of Higher Education Day, celebrate FIU’s earning its latest Carnegie recognition — and meet recent alumni who are ...

New dementia diagnoses have significantly decreased since 2015, a study published in BMJ found.But more people are living ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Court filings give insight into why shooting suspect Louis Mangione might have targeted the UnitedHealthcare executive: "It checks every box." In other news: Hospital construction trends include AI; ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...